Advertisement

Cell Biophysics

, Volume 24, Issue 1–3, pp 37–43 | Cite as

Glioblastoma therapy by direct intralesional administration of I-131 radioiodine labeled antitenascin antibodies

  • P. Riva
  • A. Arista
  • C. Sturiale
  • V. Tison
  • S. Lazzari
  • G. Franceschi
  • A. Spinelli
  • M. Casi
  • G. Sarti
  • F. Campori
  • N. Riva
Article

Abstract

Thirty patients with recurrent glioblastomas (29 brain, 1 spinal cord) received intralesional radioimmunotherapy aiming to control the progression of the tumor after surgery and radiotherapy. The BC-2 and/or BC-4 murine MAbs (Sorin-Biomedica, Saluggia, Italy) were utilized. They strongly react against tenascin (TN), which is an extracellular antigen expressed in large amounts by the stroma of glioblastoma but not by normal brain. The MAbs were labeled with I-131 and were injected directly into the tumor mass to maximize the antibody concentration in the tumor and to irradiate the neoplastic cells. The dose consisted, on average, of 3 mg antibody and 1100 MBq I-131. In most cases the radioimmunotherapy (RIT) applications were repeated two, three, or four times. No systemic adverse reactions were recorded. The brain tolerance to direct antibodies injection was quite good. The antibody concentration in the tumor was high and the MAb residence time in neoplastic tumor was prolonged. Consequently the mean radiation dose to the tumor was high: >25,000 cGy/cycle. Of 23 evaluable patients, we recorded 7 tumor stabilization (lasting, on mean, 9.1 mo), 4 partial remission (10 mo), and 4 complete remission (18 mo). The overall response rate was 34.7%.

Index Entries

Monoclonal antibodies radioimmunotherapy radioisotopes glioblastoma brain tumors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chang, C. H., Horton, J., Schoenfeld, D., Salazer, O., Perez-Tamaro, R., Kramer, S., et al. (1983)Cancer 52, 997.PubMedCrossRefGoogle Scholar
  2. 2.
    Jellinger, K., Vole, D., Grisold, W., Weiss, R., and Flament, H. (1983)Proc. 13th Internat. Chemother. Congr. 249, pp. 6–13.Google Scholar
  3. 3.
    Britton, K. E., Mather, S. J., and Granowska, M. (1991)Nucl. Med. Commun. 12, 333–347.PubMedCrossRefGoogle Scholar
  4. 4.
    Riva, R., Arista, A., Sturiale, C., Moscatelli, G., Tison, V., Mariani, M., et al. (1992)Int. J. Cancer 51, 7.PubMedCrossRefGoogle Scholar
  5. 5.
    Natali, P. G. and Zardi, L. (1989)Int. J. Cancer: Suppl 4, 66.CrossRefGoogle Scholar
  6. 6.
    Zalutsky, M. R., Moseley, R. P., Coakam, H. B., Coleman, R. E., and Bigner, D. D. (1989)Cancer Res. 49, 2807.PubMedGoogle Scholar
  7. 7.
    De Lellis, R. A., Sternberg, R. A., Mann, R. B., Banks, P. M., and Nakane, P. K. (1979)Am. J. Clin. Pathol. 71, 483.Google Scholar
  8. 8.
    MIRD Pamphlet, no. 11 (1985) Society of Nuclear Medicine, NY.Google Scholar
  9. 9.
    Loevinger, R. and Berman, M. (1968)J. Nucl. Med. 9 (suppl. 1), 7.Google Scholar
  10. 10.
    Dillman R. O. (1990)Antibody Immunoconj. Radiopharm. 3, 18.Google Scholar
  11. 11.
    WHO (1979) Handbook for reporting results of cancer treatments. Offsets Publication n. 48, Geneva.Google Scholar
  12. 12.
    Hird, V., Snook, C., Kosmas, B., Dhokia, S., Stewart, P., Mason, J., et al. (1991) Intraperitoneal radioimmunotherapy with yttrium-90-labelled immunoconjugates, inMonoclonal Antibodies: Application in Oncology (Epenetos, A., ed.), Chapman and Hall, London, pp. 267–271.Google Scholar
  13. 13.
    Schroff, R. W., Weiden, P. L., Appelbaum, J., Fer, M., Breitz, H., Vanderheuden, J.-L., et al. (1990)Antibody. Immunoconj. Radiopharmac. 2, 99.Google Scholar

Copyright information

© Humana Press Inc. 1994

Authors and Affiliations

  • P. Riva
    • 1
  • A. Arista
    • 2
  • C. Sturiale
    • 2
  • V. Tison
    • 3
  • S. Lazzari
    • 1
  • G. Franceschi
    • 1
  • A. Spinelli
    • 1
  • M. Casi
    • 1
  • G. Sarti
    • 1
  • F. Campori
    • 1
  • N. Riva
    • 1
  1. 1.Nuclear Medicine Dept. and Istituto Oncologico RomagnoloHealth Physic Dept. “M. Bufalini” HospitalCesenaItaly
  2. 2.Neurosurgery DeptHealth Physic Dept. “M. Bufalini” HospitalCesenaItaly
  3. 3.Pathology Dept.Health Physic Dept. “M. Bufalini” HospitalCesenaItaly

Personalised recommendations